# Saakshi Medtech & Panels share price today (Saakshi Medtech & Panels Ltd, NSE: SAAKSHI)

> Saakshi Medtech & Panels share price today: ₹368.90 at the NSE close on 3 November 2026. Saakshi Medtech & Panels (NSE: SAAKSHI) is worth ₹726 crore and trades at a P/E of 59.0. > Saakshi Medtech & Panels Ltd's results are improving, and its P/E is near the top of its own history, higher than 85% of past readings. SAAKSHI · Electric Equipment - General · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/saakshi-medtech-panels-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹368.90
- P/E: 59.0× (higher than 85% of the last 3.1 years)
- Revenue (Mar 2026): ₹57.0 Cr (+18.8% on a year ago)
- Profit (Mar 2026): ₹6.0 Cr (+500.0% on a year ago)
- Operating margin: 20.0% (+12.0 points on a year ago)
- ROCE: 14%, FY26
- ROIC: 9.6%, against a 12.0% cost of capital: −2.4 points
- Profit that came in as cash: 104%, last 3 years

The main question: results are strong, and the P/E is higher than 85% of its own history. ## What is the Saakshi Medtech & Panels share price today? Saakshi Medtech & Panels Ltd's share price was ₹368.90 at the close on 3 November 2026. It has been rising for 40 weeks. That is 32.5% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 16 weeks in a row. Since its first close in our records, on 8 May 2026, it has traded between ₹231 and ₹377, and at that close it sat 94% of the way up from that low. Over the last 6 months the share price moved +37% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Saakshi Medtech & Panels this quarter? 6 points in one quarter, operating margin up 12 points on a year earlier and number of shareholders down 34% in a year. 1. Promoters cut their stake by 7.6 points in one quarter From 74.8% to 67.2% in the September 2026 quarter. 2. Operating margin up 12 points on a year earlier 20% in the March 2026 quarter, from 8%. 3. Number of shareholders down 34% in a year 1,259 shareholders in the September 2026 quarter, against 1,913 a year earlier. ## What are Saakshi Medtech & Panels' latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Saakshi Medtech & Panels reported revenue of ₹57.0 crore, up 18.8% from ₹48.0 crore a year earlier, and a profit of ₹6.00 crore, up 500.0% from ₹1.00 crore. ### Saakshi Medtech & Panels results: January to March 2026 against a year earlier

| Measure | January to March 2026 | January to March 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹57.0 crore | ₹48.0 crore | +18.8% |
| Profit | ₹6.00 crore | ₹1.00 crore | +500.0% |
| Earnings per share | ₹3.21 | ₹0.71 | +352.1% |
| Operating margin | 20.0% | 8.0% | +12.0 points |

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. The newest call in our records is from 28 November 2025, about July to September 2025; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.)

## What is the Saakshi Medtech & Panels share price history? Saakshi Medtech & Panels closed at ₹368.90 on 3 November 2026. Its highest weekly close since May 2026 was ₹377.00 on 16 October 2026. ### Saakshi Medtech & Panels share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹362.60 | +1.7% |
| 1 month ago · 1 Oct 2026 | ₹365.00 | +1.1% |
| 6 months ago · 8 May 2026 | ₹269.05 | +37.1% |
| Earliest weekly close in our records · 8 May 2026 | ₹269.05 | +37.1% |
| Highest weekly close since May 2026 · 16 Oct 2026 | ₹377.00 | −2.1% |
| Lowest weekly close since May 2026 · 22 May 2026 | ₹231.00 | +59.7% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (29 weekly closes from 8 May 2026 to 3 November 2026.)

## What is the latest news on Saakshi Medtech & Panels? 3 Nov 2026: Saakshi Medtech & Panels closed at ₹368.90, up 1.7% on the week and up 1.1% on the month. Results for January to March 2026: Revenue up 18.8% and profit up 500.0% on a year earlier. ### Earlier

- 28 Nov 2025: Saakshi Medtech & Panels held its results call for July to September 2025. ## What dividend does Saakshi Medtech & Panels pay? Saakshi Medtech & Panels has paid no dividend on the NSE since its first NSE close in our records (8 May 2026), the start of the period we checked. No. Saakshi Medtech & Panels Ltd paid out 0% of its profit as dividends in each of its last 7 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Saakshi Medtech & Panels management say on the latest results call? On the call for July to September 2025, held on 28 November 2025, Saakshi Medtech & Panels' management spoke about the quarter; the main points are below. > “This facility is a platform for scaling up, optimizing for a high mix and a high value manufacturing. The relocation is underway; the transition to the new 41,000 square feet integrated facility is on schedule, bringing some of our major operations under one roof. …”
> Anikhet Ladkar, Chairman and Managing Director, on the call for July to September 2025

Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/56459-28-Nov-2025.pdf). (From the call for July to September 2025, 28 November 2025. The January to March 2026 results are out since, so this part may be out of date until we update it.)

## What is the future of Saakshi Medtech & Panels? What is changing in the business? What is changing at Saakshi Medtech & Panels, from the latest results and calls: aerospace production and qualification, integrated facility consolidation and radiator and heat-exchanger opportunity. - Aerospace production and qualification. Aerospace moved from qualification work into serial production, with further customer onboarding under way. ⚠ estimate
- Integrated facility consolidation. The new facility can combine operations, remove rental expense and support higher-value manufacturing. ⚠ estimate
- Radiator and heat-exchanger opportunity. Radiators can diversify revenue once facility capacity and customer orders convert. ⚠ estimate

We check 16 kinds of change in every company, such as costs spread over more sales, higher-value products, new orders, new regions or falling debt, against its reported numbers and what management said on its calls. Only changes the numbers back are shown. (Our read after the January to March 2026 results, written 19 July 2026.)

## What is Saakshi Medtech & Panels' order book? Management said that typical order-book visibility was only three months. - Management said that a customer order book remained to be executed over the next four years. ✓ fact

(Our read after the January to March 2026 results, written 19 July 2026.)

## What could change the Saakshi Medtech & Panels story? What are the risks? If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. ### Each change stops working if

- Aerospace production and qualification: Existing aerospace production does not grow and additional customer qualifications do not convert into production orders. - Integrated facility consolidation: The facility does not reduce operating friction or requires additional debt-funded capital spending beyond the stated remaining work. - Radiator and heat-exchanger opportunity: Customer order conversion remains delayed after facility capacity becomes available. ### The main risks

- Working-capital and cash absorption: Capital spending and inventory intensity can delay conversion of the operating recovery into free cash flow. ✓ fact
- Disclosure inconsistency: Conflicting statements on asset utilisation, revenue outlook and backlog limit confidence in forward estimates. ✓ fact
- Short margin history: The margin recovery is positive, but the available history is too short to establish a durable normal margin. ✓ fact

(Our read after the January to March 2026 results, written 19 July 2026.)

## What to watch in Saakshi Medtech & Panels' next results? When Saakshi Medtech & Panels reports April to June 2026, these are the 3 checks that show whether the story is still on course. First: Operating cash flow remains below reported net profit after facility completion. | What to check | Why |
| --- | --- |
| Operating cash flow remains below reported net profit after facility completion. | Working-capital and cash absorption |
| The next call supplies a reconciled backlog, asset-utilisation and revenue bridge. | Disclosure inconsistency |
| Operating margin falls back toward the FY25 level after the facility comes on stream. | Short margin history |

## Which stock lists is Saakshi Medtech & Panels on? Saakshi Medtech & Panels is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 729.7355371900826](https://www.sectoralpha.in/momentum-stocks-india)

## Is Saakshi Medtech & Panels profitable? Saakshi Medtech & Panels Ltd earned ₹6.0 Cr of net profit in the Mar 2026 quarter, +500.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹12.0 Cr. Over 6 years profit has grown 12.2% a year on average. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr. For the full year, FY26 profit was ₹12.0 Cr (+140.0% on the year before). Why profit moved: revenue changed +18.8% on a year earlier and the margin moved +12.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +125.0% and revenue +0.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported. FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much revenue does Saakshi Medtech & Panels make, and is it growing? Saakshi Medtech & Panels Ltd reported ₹57.0 Cr of revenue in the Mar 2026 quarter, +18.8% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 6 years it has grown 11.3% a year on average. The last full year, FY26, came in at ₹116 Cr. FY26 revenue was ₹116 Cr, +26.1% on the year before. Recent pace: the last four quarters grew +0.3% on average, against 11.3% a year over the longer run, so this year is growing slower than its own long-run rate. FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported. FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## How much of every ₹100 of sales does Saakshi Medtech & Panels keep? Saakshi Medtech & Panels Ltd's operating margin was 20.0% in the Mar 2026 quarter, 12.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Over the last four quarters it has moved +3.0 percentage points. Across 7 years it has been between 10.0% and 19.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3.6 percentage points on the year while gross margin changed +7.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported. FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported. Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters. ## Is Saakshi Medtech & Panels' profit turning into cash? Over the last 3 years, 104% of Saakshi Medtech & Panels Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹18.0 Cr of operating cash against ₹12.0 Cr of profit. After ₹25.0 Cr of spending on assets, free cash was −₹7.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 104% of profit came in as cash: the cash cycle got 56 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 5.5× depreciation over three years. The next section checks what that spending is building. ## Where does Saakshi Medtech & Panels' cash go? Saakshi Medtech & Panels Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 144 days in FY26, up from 88 days in FY21. It spent ₹72.0 Cr on assets over the last 3 years. Customers take 83 days to pay, and stock sits for 122 days on average. Why this happened. Management linked the radiator opportunity to the expanded facility and customer execution. It remains a prospective rather than reported source of earnings. At FY26 sales of ₹116 Cr, each day of that cycle ties up about ₹0.3 Cr, so roughly ₹46.0 Cr is tied up in the business at any time. FY26: customers took 83 days to pay and stock sat for 122 days, about 4.0 months of sales sitting as stock, for a full cycle of 144 days, longer than FY21's 88. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 122 days. Customers pay about 83 days after that. Suppliers are paid at 60 days. Together that makes the 144-day cycle. Spending on assets: ₹72.0 Cr over the last 3 years, against ₹13.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹10.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Saakshi Medtech & Panels' P/E ratio, and how does it compare with its own history? Saakshi Medtech & Panels Ltd's P/E is 59.0×, near the high end of its own history: higher than 85% of past readings. Its usual P/E (the middle reading) is 39.1×, over 3.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Saakshi Medtech & Panels business getting better or worse? Saakshi Medtech & Panels Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 5 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## What is the Saakshi Medtech & Panels story, and has it been checked? Saakshi Medtech & Panels Ltd's story is not scored yet against the checks our research set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Still open: If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. From the price. Price stage 2, week 40, above its 200-day line, relative strength rising. From the research. Saakshi has recovered from the FY25 margin trough, while aerospace, the integrated facility and heat exchangers offer growth paths; thin reporting history, working-capital intensity and conflicting management visibility…

What is not proven yet. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. What would change our mind. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. The test written in advance. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. Measured by: the thesis as written as stated by the next result. The test written in advance. Working-capital and cash absorption. Measured by: Working-capital and cash absorption Operating cash flow remains below reported net profit after facility completion. by the next result. The test written in advance. Disclosure inconsistency. Measured by: Disclosure inconsistency The next call supplies a reconciled backlog, asset-utilisation and revenue bridge. by the next result. What the company does. The reported FY26 recovery followed the FY25 trough and retained higher operating profitability in the latest reported period. Aerospace production, facility consolidation and radiators offer several growth paths, but customer conversion remains unproven in the reported data. Cash remains tied up in expansion and working capital, while the supplied consistency analysis identifies conflicts in forward disclosure. What the surface reading misses. The surface reading is: The annual recovery suggests profitability has moved beyond the FY25 trough. The research reads it further: The higher margin coincides with revenue recovery and management's cost-control explanation, but the available margin series is short and facility depreciation has not yet been tested. What the surface reading misses. The surface reading is: Operating cash flow improved in the latest year. The research reads it further: The company is still spending on expansion, so improved operating cash flow has not yet translated into free cash generation. Sources: our stock research file (19 July 2026) · quarterly results through Mar 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Saakshi Medtech & Panels management deliver what it promised? What Saakshi Medtech & Panels Ltd's management promised, against what actually happened: 3 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. Conflicting Revenue Potential from Asset Base · 28 November 2025. Within the same November 2025 call, management provided starkly contradictory statements on the company's revenue potential from its asset base. The CFO stated a potential of 150 crores, which was shortly thereafter contradicted by the MD who claimed a potential of 500 crores, creating significant uncertainty about the company's true capacity and internal alignment. Earlier call (Nov 2025): “The potential revenue from the assets is at around 150 crores.” Later call (Nov 2025): “my estimation is that with that kind of a gross block coming in, we should be close to around 500 crores of revenue realization is something that we would be in a position to target.”

Inconsistent FY26 Revenue Outlook · 28 November 2025. Management gave conflicting signals regarding the full-year revenue outlook for FY26 within the November 2025 call. Initially, the MD implied circa 125 crores for the full year by guiding for a typical 15% H2-over-H1 growth. Later in the same call, management endorsed an analyst's figure of 140 crores, creating a material 15 crore gap without explanation. Earlier call (Nov 2025): “typically there is a close to around 15% growth which we see between H1 and H2. We don”. Later call (Nov 2025): “We should be somewhere close to that.”

Contradictory Statements on Order Book Visibility · 28 November 2025. In the November 2025 call, management's statements on order book visibility were contradictory. The MD initially claimed the company has 'only a three-month visibility' for its order book. However, later in the call, he detailed a specific '230 odd crores of order book is yet to be executed over the next four years' for a single customer, directly contradicting the earlier assertion of limited forward visibility. Earlier call (Nov 2025): “typically we have only a three-month visibility in terms of what is the order book that is available with us.” Later call (Nov 2025): “Close to around 230 odd crores of order book is yet to be executed over the next four years.”

Every quote above is taken word for word from the company’s own earnings calls. ## How much does Saakshi Medtech & Panels earn on its capital? Saakshi Medtech & Panels Ltd earned a ROCE of 14% in FY26. That is up from a low of 6% in FY25. Its return on capital used (ROIC) is 2.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 10.3% net margin and 0.74× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 10.3% net margin × 0.74× asset turnover × 1.41× leverage (assets divided by equity) ≈ 10.7% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 9.6% − 12.0% = −2.4 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Saakshi Medtech & Panels have too much debt? Saakshi Medtech & Panels Ltd has total debt of ₹25.0 Cr against shareholder equity of ₹110 Cr as of Mar 2026, so its debt is 0.23× its equity, which is very little. Year by year, that ratio went from 0.19 in FY24 to 0.23 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Saakshi Medtech & Panels shareholding pattern? Promoters cut their stake in Saakshi Medtech & Panels Ltd by 6.5 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 67.2% of the company. Domestic institutions moved −1.4 points over the same period, to 0.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −6.5 points over 8 quarters, to 67.2%; Domestic institutions: −1.4 points over 8 quarters, to 0.4%; Foreign institutions: +0.0 points over 8 quarters, to 0.1%. Why the owners changed: promoters drove it (−6.5 points), together with domestic institutions (−1.4 points). They reduced their stake. ## How far is Saakshi Medtech & Panels from balance-sheet trouble? For Saakshi Medtech & Panels Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Saakshi Medtech & Panels rank in its industry? 50.4 out of 100, rank 14 of 14 in Electric Equipment - General, with 39% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Saakshi Medtech & Panels Ltd scores 50.4 out of 100 against the 14 companies it is compared with in Electric Equipment - General, ranking 14. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 19.5 + 12.8 + 6.5 + 11.6 = 50.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Saakshi Medtech & Panels compared with? Saakshi Medtech & Panels ranks 14 of 14 Electric Equipment - General companies on the 4-Factor Sector Score, with 50.4 out of 100. 1. [Emmvee Photovoltaic Power Ltd](https://www.sectoralpha.in/stocks/emmvee-photovoltaic-power-ltd) EMMVEE · quiet · Most evidence points up · 73% evidence 73.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/43.75 · Revenue 60.2% · Profit 93.7% · Operating margin change 0 points · 100% evidence Capital efficiency 25.9/31.25 · ROCE 44.6% · Operating margin 35% · 100% evidence Valuation 20.3/25 · P/E 11.2× · PEG 0.68 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 26.8 + 25.9 + 20.3 = 73 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 2. [Fujiyama Power Systems Ltd](https://www.sectoralpha.in/stocks/fujiyama-power-systems-ltd) UTLSOLAR · losing its lead · Most evidence points up · 69% evidence 66.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.4/43.75 · Revenue 95% · Profit 62.4% · Operating margin change 1 points · 88% evidence Capital efficiency 20.3/31.25 · ROCE 35.1% · Operating margin 19% · 100% evidence Valuation 19.2/25 · P/E 26.8× · PEG 0.56 · 65% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 27.4 + 20.3 + 19.2 = 66.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 3. [Hindusthan Insulators & Industries Ltd](https://www.sectoralpha.in/stocks/hindusthan-insulators-industries-ltd) leader · Evidence leans up · 72% evidence 63.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 72% · Profit 100% · Operating margin change 34 points · 71% evidence Capital efficiency 8.2/25 · ROCE 10.6% · Operating margin 44% · 95% evidence Valuation 10.8/20 · P/E 12.7× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 97.4% · Lead over NIFTY 500 144% · 1 year 432.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.9 + 8.2 + 10.8 + 20 = 63.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Yash Highvoltage Ltd](https://www.sectoralpha.in/stocks/yash-highvoltage-ltd) leader · Too little evidence to rank firmly · 56% evidence 62.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 26% evidence Capital efficiency 16.1/25 · ROCE 28.6% · Operating margin 28% · 95% evidence Valuation 8.7/20 · P/E 58.7× · PEG n/a · 15% evidence Relative strength 18.1/20 · Lead over its industry 38.3% · Lead over NIFTY 500 79.6% · 1 year 137.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 16.1 + 8.7 + 18.1 = 62.3 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Parth Electricals & Engineering Ltd](https://www.sectoralpha.in/stocks/parth-electricals-engineering-ltd) PARTH · leader · Too little evidence to rank firmly · 52% evidence 47.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.1/35 · Revenue n/a · Profit n/a · Operating margin change -1 points · 27% evidence Capital efficiency 10.4/25 · ROCE 21% · Operating margin 11% · 100% evidence Valuation 9.4/20 · P/E 38.2× · PEG n/a · 15% evidence Relative strength 12.3/20 · Lead over its industry 3.6% · Lead over NIFTY 500 36.3% · 1 year 76.6% · 70% evidence · 12 of 12 weeks ahead Exact sum: 15.1 + 10.4 + 9.4 + 12.3 = 47.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. [ABB India Ltd](https://www.sectoralpha.in/stocks/abb-india-ltd) ABB · losing its lead · Evidence leans down · 71% evidence 45.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 10.2% · Profit 66.5% · Operating margin change -1 points · 62% evidence Capital efficiency 14.2/25 · ROCE 29.9% · Operating margin 13% · 76% evidence Valuation 9.2/20 · P/E 88.2× · PEG n/a · 50% evidence Relative strength 4.6/20 · Lead over its industry -24.8% · Lead over NIFTY 500 4.8% · 1 year 22.9% · 100% evidence · 5 of 12 weeks ahead Exact sum: 17.8 + 14.2 + 9.2 + 4.6 = 45.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Vidya Wires Ltd](https://www.sectoralpha.in/stocks/vidya-wires-ltd) VIDYAWIRES · quiet · Too little evidence to rank firmly · 59% evidence 44.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/43.75 · Revenue 31.6% · Profit 40.9% · Operating margin change -0.5 points · 88% evidence Capital efficiency 11.9/31.25 · ROCE 20.6% · Operating margin 4% · 100% evidence Valuation 12.7/25 · P/E 27.6× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 19.8 + 11.9 + 12.7 = 44.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. [Saatvik Green Energy Ltd](https://www.sectoralpha.in/stocks/saatvik-green-energy-ltd) SAATVIKGL · quiet · Evidence leans down · 83% evidence 40.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.3/35 · Revenue 46.5% · Profit -21.9% · Operating margin change -12.7 points · 88% evidence Capital efficiency 12.7/25 · ROCE 33% · Operating margin 6.6% · 100% evidence Valuation 15.0/20 · P/E 17.6× · PEG 0.84 · 65% evidence Relative strength 3.5/20 · Lead over its industry -39.8% · Lead over NIFTY 500 -13.8% · 1 year -34.5% · 70% evidence · 0 of 12 weeks ahead Exact sum: 9.3 + 12.7 + 15 + 3.5 = 40.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 9. [Indosolar Ltd](https://www.sectoralpha.in/stocks/indosolar-ltd) WAAREEINDO · basing · Evidence leans down · 68% evidence 36.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 0.8/35 · Revenue -26.8% · Profit -41.4% · Operating margin change -25.4 points · 100% evidence Capital efficiency 16.3/25 · ROCE 124% · Operating margin 9.5% · 100% evidence Valuation 11.5/20 · P/E 6.4× · PEG n/a · 15% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -47.2% · 1 year -68.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 0.8 + 16.3 + 11.5 + 7.5 = 36.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Vivid Electromech Ltd](https://www.sectoralpha.in/stocks/vivid-electromech-ltd) VIVIDEL · losing its lead · Too little evidence to rank firmly · 43% evidence 59.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/43.75 · Revenue n/a · Profit n/a · Operating margin change 1 points · 45% evidence Capital efficiency 21.7/31.25 · ROCE 58.9% · Operating margin 20% · 95% evidence Valuation 12.3/25 · P/E 28.6× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 25.6 + 21.7 + 12.3 = 59.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 11. [Cospower Engineering Ltd](https://www.sectoralpha.in/stocks/cospower-engineering-ltd) Too little evidence to rank firmly · 28% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [GP Eco Solutions India Ltd](https://www.sectoralpha.in/stocks/gp-eco-solutions-india-ltd) GPECO · quiet · Too little evidence to rank firmly · 32% evidence 55.3 out of 100 Growth Capital Valuation Relative
13. [Indo SMC Ltd](https://www.sectoralpha.in/stocks/indo-smc-ltd) losing its lead · Too little evidence to rank firmly · 28% evidence 50.5 out of 100 Growth Capital Valuation Relative
14. Saakshi Medtech & Panels Ltd this page SAAKSHI · breaking out · Too little evidence to rank firmly · 39% evidence 50.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Revenue n/a · Profit n/a · Operating margin change 12 points · 15% evidence Capital efficiency 12.8/25 · ROCE 14.3% · Operating margin 20% · 75% evidence Valuation 6.5/20 · P/E 58.1× · PEG n/a · 50% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 54.7% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 19.5 + 12.8 + 6.5 + 11.6 = 50.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Electric Equipment - General](https://www.sectoralpha.in/sectors/electric-equipment-general), all 14 compared on one page. ## Which companies are close to Saakshi Medtech & Panels in size? Saakshi Medtech & Panels is the 11th largest of 14 Electric Equipment - General companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Vivid Electromech, Indo SMC and Indosolar. Just below it: Parth Electricals & Engineering, Cospower Engineering and GP Eco Solutions India. ### Electric Equipment - General companies close in size

1. [Vivid Electromech Ltd](https://www.sectoralpha.in/stocks/vivid-electromech-ltd) ₹1,008 crore
2. [Indo SMC Ltd](https://www.sectoralpha.in/stocks/indo-smc-ltd) ₹941 crore
3. [Indosolar Ltd](https://www.sectoralpha.in/stocks/indosolar-ltd) ₹797 crore
4. Saakshi Medtech & Panels Ltd ₹714 crore
5. [Parth Electricals & Engineering Ltd](https://www.sectoralpha.in/stocks/parth-electricals-engineering-ltd) ₹659 crore
6. [Cospower Engineering Ltd](https://www.sectoralpha.in/stocks/cospower-engineering-ltd) ₹550 crore
7. [GP Eco Solutions India Ltd](https://www.sectoralpha.in/stocks/gp-eco-solutions-india-ltd) ₹464 crore

[All 14 Electric Equipment - General companies, largest first](https://www.sectoralpha.in/sectors/electric-equipment-general#all-companies)

### Companies close in size in other industries

1. [NCL Industries Ltd](https://www.sectoralpha.in/stocks/ncl-industries-ltd) ₹715 crore · Cement
2. [Everest Industries Ltd](https://www.sectoralpha.in/stocks/everest-industries-ltd) ₹714 crore · Pre-Engineering Buildings
3. Saakshi Medtech & Panels Ltd ₹714 crore
4. [Viviana Power Tech Ltd](https://www.sectoralpha.in/stocks/viviana-power-tech-ltd) ₹713 crore · EPC
5. [Magadh Sugar & Energy Ltd](https://www.sectoralpha.in/stocks/magadh-sugar-energy-ltd) ₹712 crore · Sugar

## What else do people ask about Saakshi Medtech & Panels? ### What is Saakshi Medtech & Panels's share price today? Saakshi Medtech & Panels Ltd's share price is ₹368.90. The whole company is worth ₹726 Cr on the market. In the last 52 weeks it traded between ₹231 to ₹377; today it is 94% of the way up from the low, 32.5% above its 200-day average (as of 3 November 2026). ### What were Saakshi Medtech & Panels's latest quarterly results? Saakshi Medtech & Panels Ltd reported revenue of ₹57.0 Cr and net profit of ₹6.0 Cr for the Mar 2026 quarter. Revenue rose 18.8% and profit rose 500.0% compared with a year earlier. Earnings per share were ₹3.21 (as of 3 November 2026). ### What is Saakshi Medtech & Panels's market cap? Saakshi Medtech & Panels Ltd's market capitalisation is ₹726 Cr at a share price of ₹368.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Saakshi Medtech & Panels performing? Saakshi Medtech & Panels Ltd's share price has been rising for 40 weeks. In its latest quarter, revenue rose 18.8% and profit rose 500.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 16 weeks running (as of 3 November 2026). ### Is Saakshi Medtech & Panels in an uptrend? Yes, the price has been rising for 40 weeks (stage 2 of 4), 32.5% above its 200-day average, and 94% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 3 November 2026). ### Will Saakshi Medtech & Panels's share price go up? This page does not forecast Saakshi Medtech & Panels Ltd's share price. What it shows instead: the share price is ₹368.90, and it has been rising for 40 weeks. Its P/E of 59.0× is higher than 85% of its own last 3 years (as of 3 November 2026). ### Who owns Saakshi Medtech & Panels? Promoters own 67.2% of Saakshi Medtech & Panels Ltd, foreign institutions 0.1%, domestic institutions 0.4% and the public 32.3% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 6.5 percentage points over 8 quarters (as of 3 November 2026). ### Does Saakshi Medtech & Panels have too much debt? No, Saakshi Medtech & Panels Ltd has little debt: its debt is 0.23× its equity, and its operating profit is 22 times its interest bill. FY26 borrowings were ₹25.0 Cr against equity of ₹111 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Saakshi Medtech & Panels in its business cycle? Saakshi Medtech & Panels Ltd's FY26 operating margin was 19.0%, against a 7-year range of 10.0% to 19.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 20.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Saakshi Medtech & Panels story? The main question: results are strong, and the P/E is higher than 85% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Saakshi Medtech & Panels a stock worth studying right now? What the numbers show: Saakshi Medtech & Panels Ltd's results are improving, and its P/E is near the top of its own history, higher than 85% of past readings. The main open question: whether earnings grow enough to match the multiple. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Saakshi Medtech & Panels share price forecast for 2026? What is changing at Saakshi Medtech & Panels, from the latest results and calls: aerospace production and qualification, integrated facility consolidation and radiator and heat-exchanger opportunity. What would change the story: If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.